欧美区在线视频_无套内射chinesehd熟女_日本中文视频_香港三级日本三级欧美一区_国产熟女视频_亚洲小说欧美激情另类_国产色婷婷精品福利_国产真实乱系列直播在线

中文
Pipeline

We focus on oncology. In our pipeline, 6 products are in Phase I clinical trials, and another 3 are currently under IND-enabling studies.

Product Drug Candidate
IND
Phase I
Phase II
Notes
WJ01 XPO1 inhibitor

WJ01 XPO1 inhibitor

An uniquely designed covalent XPO1 inhibitor of rapid clearance with broad-spectrum antitumor activity. It can be used to treat a variety of hematological cancers and solid tumors in clinic.

WJ02 EGFR inhibitor

WJ02 EGFR inhibitor

A small molecule EGFR inhibitor that effectively inhibits the Exon 20 insertion mutations. Preclinical data show that WJ002 maintains the activity of inhibiting common EGFR mutations such as T790M, and at the same time overcomes the insensitivity of the 3rd EGFR inhibitor to exon20 insertion mutations.

WJ03 Aurora A inhibitor

WJ03 Aurora A inhibitor

An oral available small molecule Aurora A inhibitor. Aurora A inhibitors have a synthetic lethal effect with RB1 deletion or inactivation, and can be used to treat malignant tumors with RB1 deletion or inactivation such as small cell lung cancer and triple-negative breast cancer.

WJ04 EGFR inhibitor

WJ04 EGFR inhibitor

An effective fourth-generation EGFR inhibitor. Preclinical data show that the drug has a good inhibitory activity against acquired EGFR mutations, including Del19/T790M/C797S and L858R/T790M/C797S that are insensitive to third-generation EGFR inhibitors, and shows high selectivity over wild-type EGFR.

WJ05 Wee1 inhibitor

WJ05 Wee1 inhibitor

Undisclosed

WJ06 FAK inhibitor

WJ06 FAK inhibitor

Undisclosed

WJ07 KIF18A inhibitor

WJ07 KIF18A inhibitor

Undisclosed

WJ08

WJ08

Undisclosed

WJ09

WJ09

Undisclosed

WJ10

WJ10

Undisclosed

WJ11

WJ11

Undisclosed



Note: Reference only for professionals



Contact Us